Lung cancer cells have differential signaling responses to KRAS inhibitor treatment

(H. Lee Moffitt Cancer Center & Research Institute) In a new article published in Clinical Cancer Research, Moffitt Cancer Center researchers show that various subtypes of lung cancer cells activate different signaling pathways in response to KRASG12C inhibitor treatment. These results may help identify potential combination therapy approaches and guide treatment decisions for lung cancer patients in the future.